Answers are grounded in this paper and cite their sources.
Indrouction: Despite the limited pieces of evidence on the cardiovascular safety of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH) and functional hypogonadism (FH), its global use for hypogonadism management is surging. This review aims to determine TRT’s long-term safety. Methods: A systematic review was conducted using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Six databases (PubMed, Scopus, Wiley Library, Embase, Cochrane database for systematic reviews and Google Scholar) were searched for relevant articles. The Distiller-SR software was used for journal screening, duplicate removal and data extraction. Results: This review included 23 eligible publications (10 RCTs and 13 cohort studies) involving 102,139 participants. Although only seven studies reported major adverse cardiovascular events (MACE) outcomes, many others examined cardiovascular risk factor benefits and or adverse effects. Conclusion: Long-term use of TRT in men with LOH and FH appears to offer cardiovascular benefits, provided safe practices are followed. However, caution is advised on the use of TRT in hypogonadal men with pre-existing cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Olopade et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: